Geisinger Heart Institute, Wilkes-Barre, Pennsylvania.
Geisinger Heart Institute, Wilkes-Barre, Pennsylvania.
Heart Rhythm. 2018 May;15(5):696-702. doi: 10.1016/j.hrthm.2017.12.022. Epub 2017 Dec 20.
Right ventricular pacing (RVP) is associated with heart failure and increased mortality. His-bundle pacing (HBP) is a physiological alternative to RVP.
The purpose of this study was to report long-term performance and compare the clinical outcomes of permanent HBP vs RVP.
All patients requiring pacemaker implantation underwent an attempt at permanent HBP in 2011 at one hospital and RVP at the sister hospital. Patients were followed from implantation, 2 weeks, 2 months, and yearly for 5 years. Left ventricular ejection fraction (LVEF), pacing thresholds, lead revision, and generator change were tracked. Primary outcome was the combined endpoint of death or heart failure hospitalization (HFH) at 5 years.
HBP was attempted in 94 consecutive patients and was successful in 75 (80%); 98 patients underwent RVP. LVEF remained unchanged in the HBP group (55% ± 8% vs 57% ± 6%; P = .13), whereas significant decline was noted in the RVP group (57% ± 7% vs 52% ± 11%; P = .002). Incidence of pacing-induced cardiomyopathy was significantly lower in HBP compared to RVP patients (2% vs 22%; P = .04). At 5 years, death or HFH was significantly lower in HBP compared to RVP patients with >40% ventricular pacing (32% vs 53%; hazard ratio 1.9; P = .04). At 5 years, the need for lead revisions (6.7% vs 3%) and for generator change (9% vs 1%) were higher in the HBP group.
In patients undergoing pacemaker implantation, permanent HBP was associated with reduction in death or HFH during long-term follow-up compared to RVP. HBP was associated with higher rates of lead revisions and generator change.
右心室起搏(RVP)与心力衰竭和死亡率增加有关。希氏束起搏(HBP)是 RVP 的一种生理性替代方法。
本研究旨在报告永久性 HBP 与 RVP 的长期性能,并比较其临床结果。
2011 年,一家医院所有需要植入起搏器的患者均尝试进行永久性 HBP,另一家医院则进行 RVP。患者从植入后、2 周、2 个月和每年随访 5 年。跟踪左心室射血分数(LVEF)、起搏阈值、导联修订和发电机更换情况。主要终点是 5 年内死亡或心力衰竭住院(HFH)的复合终点。
94 例连续患者尝试进行 HBP,其中 75 例(80%)成功;98 例患者接受 RVP。HBP 组 LVEF 保持不变(55%±8%比 57%±6%;P=0.13),而 RVP 组明显下降(57%±7%比 52%±11%;P=0.002)。与 RVP 患者相比,HBP 患者起搏诱导性心肌病的发生率显著降低(2%比 22%;P=0.04)。在 5 年时,与 RVP 患者相比,HBP 患者的死亡率或 HFH 发生率明显降低,心室起搏比例>40%(32%比 53%;风险比 1.9;P=0.04)。在 5 年时,HBP 组需要进行导联修订(6.7%比 3%)和发电机更换(9%比 1%)的患者比例更高。
在接受起搏器植入的患者中,与 RVP 相比,永久性 HBP 在长期随访期间与降低死亡率或 HFH 相关。HBP 与更高的导联修订和发电机更换率相关。